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to the point that methods of manipulating these factors
are under development. One such technology is genetic
modification of vein grafts just before arterial bypass to
impair IH. Gene therapy has been shown to be successful
at reducing IH after arterial injury in both small and large
animals, as well as reducing IH resulting from transplant-
related vasculopathy.2 Similar approaches may be effica-
cious in preventing vein graft IH.
Nitric oxide (NO) has a number of vasoprotective
properties that include the ability to inhibit platelet adher-
ence3 and leukocyte chemotaxis,4 inhibit vascular smooth
muscle cell proliferation5 and migration,6,7 and promote
endothelial cell growth8 and survival.9,10 These properties
serve as the underlying bases for the development of NO
synthase (NOS) gene therapy for vascular disease. To date,
all three NOS isoforms have been transferred into blood
vessels for various vascular disorders.11-21 We have shown
that adenoviral gene transfer of the human inducible NOS
(iNOS) gene to both injured rat and pig arteries dramati-
cally inhibit IH14 and also prevented transplant-related
vasculopathy in rats after allogeneic aortic transplanta-
tion.15 However, the effect of iNOS gene transfer on vein
grafts has not been evaluated. Given the vasoprotective
properties of NO and the efficacy of NOS-based gene
transfer to the arterial wall, the aim of this study was to
Vein graft failure in the treatment of cardiovascular
disease remains a significant clinical and economic con-
cern.1 Over the last decade, our understanding of the biol-
ogy of the vessel wall and of the cellular and humoral
influences that contribute to the pathophysiologic condi-
tion of vein graft intimal hyperplasia (IH) has progressed
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Objective: The aim of this study is to determine whether adenoviral inducible nitric oxide synthase (iNOS) gene transfer
could inhibit intimal hyperplasia (IH) in porcine internal jugular veins interposed into the carotid artery circulation.
Methods: Porcine internal jugular veins were transduced passively with 1 × 1011 particles of an adenoviral vector carrying
either the human iNOS (AdiNOS) or β-galactosidase (AdlacZ) cDNA for 30 minutes and then interposed into the carotid
artery circulation. Segments of each vein graft were maintained in an ex vivo organ culture to measure nitrite accumulation,
a marker of nitric oxide synthesis. The grafts were analyzed immunohistochemically for the presence of neutrophils,
macrophages, and leukocytes by staining for myeloperoxidase, ED1, and CD45, respectively, at 3 (n = 4) and 7 (n = 4) days.
Morphometric analyses and cellular proliferation (Ki67 staining) were assessed at 3 (n = 4), 7 (n = 4), and 21 days (n = 8).
Results: AdlacZ-treated vein grafts demonstrated high levels of β-galactosidase expression at 3 days with a gradual decline
thereafter. Nitrite production from AdiNOS-treated vein grafts was approximately fivefold greater than AdlacZ-treated
grafts (P = .00001). AdiNOS or AdlacZ treatment was associated with minimal graft inflammation. Cellular prolifera-
tion rates were significantly reduced in AdiNOS-treated grafts as compared with controls at both 3 (41%, P = .000004)
and 7 days (32%, P = .0001) after bypass. This early antiproliferative effect was most pronounced at the distal anasto-
mosis (65%, P = .0005). The iNOS gene transfer reduced the intimal/medial area ratio in vein grafts at 7 (36%, 
P = .009) and 21 days (30%, P = .007) versus controls. This inhibition of IH was again more prominent in the distal
segments of the grafts (P = .01).
Conclusion: Adenovirus-mediated iNOS gene transfer to porcine internal jugular vein grafts effectively reduced cellular
proliferation and IH. Although iNOS gene transfer reduced IH throughout the entire vein graft, the most pronounced
effect was measured at the distal anastomosis. These results suggest potential for iNOS-based genetic modification of
vein grafts to prolong graft patency. (J Vasc Surg 2001;34:156-65.)
determine whether adenoviral iNOS gene transfer would
be similarly beneficial in inhibiting vein graft IH.
MATERIAL AND METHODS
Adenoviral vectors. A first-generation E1- and E3-
deleted adenoviral vector carrying either the human iNOS
cDNA22 (AdiNOS) or β-galactosidase cDNA (AdlacZ)
was constructed as previously described.14,15 The titer of
AdiNOS was ~1 × 1011 particles/mL (~109 plaque-form-
ing units per milliliter [pfu/mL]) and AdlacZ was ~1 ×
1013 particles/mL (~1011 pfu/mL).
Animals and surgical procedure. All animal proce-
dures were performed by use of aseptic technique in accor-
dance with the Institutional Animal Care and Use
Committee of the University of Pittsburgh. Domestic
juvenile castrated male pigs (Walter Whippo, Enon Valley,
Pa) weighing 12 to 15 kg were anesthetized with intra-
venous sodium pentobarbital and inhalational isoflurane
and nitrous oxide. Antibiotic prophylaxis was provided
with one dose of cefazolin before and after operation.
Bilateral carotid arteries and internal jugular (IJ) veins
were exposed through a midline neck incision. A 6-cm
segment of IJ vein was harvested, rinsed in normal saline
solution, and placed into 1 mL of Optimem (Gibco BRL,
Rockville, Md) containing 1 × 1011 particles of either
AdiNOS or AdlacZ. After 30 minutes incubation at room
temperature, the vein was rinsed, and a 1.0-cm ring seg-
ment of vein was placed in organ culture media. Five min-
utes before carotid arterial occlusion, the animal received
heparin (100 U/kg) intravenously. A 2-cm segment of the
carotid artery was resected, and the treated vein graft was
placed into the arterial circulation as an interposition graft.
End-to-end anastomoses were performed at the proximal
and distal ends with 7-0 nylon (Surgilene; USSC, Exeter,
NH). Excellent size match between the vein grafts and the
carotid arteries were noted. The neck incisions were closed
with absorbable suture (Polysorb; USSC).
Ex vivo vein segment organ culture. One-centime-
ter vein segments were cultured in Dulbecco modified
Eagle’s medium (low glucose)/Ham’s F12 (1:1 vol:vol)
(BioWhittaker, Walkersville, Md) supplemented with 10%
fetal bovine serum, penicillin 100 U/mL, streptomycin
100 µg/mL, and L-glutamine 4 mmol/L in a 37°C, 95%
air/5% CO2 incubator. Medium was changed daily, and
the supernatant was assayed for nitrite, a stable breakdown
product of NO, by use of the Griess reaction.23 Nitrite
production was normalized to tissue sample weight and
reported as nanomoles per gram.
Tissue processing. Vein grafts were collected at 3 (n =
4), 7 (n = 4), or 21 (n = 8) days after bypass. Animals were
anesthetized, and the vein grafts were exposed through the
prior midline incision. The proximal carotid artery was li-
gated 3 cm from the proximal anastomosis. The distal
carotid artery was transected, and 2% paraformaldehyde was
infused to distend the graft, which was then removed and
fixed in 2% paraformaldehyde for 2 hours at 4°C followed by
30% sucrose at 4°C overnight. Vessels were cut into 0.5-cm
sections and snap-frozen in liquid nitrogen. Small segments
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of small bowel were also harvested, fixed, frozen, and cut to
serve as positive controls for immunohistochemical staining.
X-gal staining for β-galactosidase activity. Frozen
sections of vein graft (7 µm) were washed twice in MgCl2
(1 mmol/L) for 15 minutes and stained with X-gal (Sigma
Chemical Co, St Louis, Mo) at 37°C overnight, and
images were obtained by light microscopy (Nikon light
microscope; Nikon, Melville, NY) to quantify positive
blue-staining cells.
Immunohistochemistry. For immunofluorescent
staining, vein sections were rinsed in phosphate-buffered
saline solution (PBS) followed by a bovine serum albumin
(BSA) mixture (100 mL PBS + 0.15 g glycine + 0.5 g
BSA), blocked with purified goat immunoglobulin G (50
mg/mL; Sigma Chemical Co), and then incubated with a
mouse monoclonal anti-Ki67 antibody (1:100; Vector
Labs, Burlingame, Calif) for 1 hour. The sections were
washed and incubated with the secondary goat antimouse
Cy3–labeled antibody (1:3000; Jackson ImmunoResearch
Laboratories, West Grove, Pa) for 1 hour. Nuclei were
stained with Hoechst 33325 (Sigma Chemical Co) for 30
seconds. Images were collected by use of a high NA
planapo objective at original magnification × 40, an
Olympus Provis microscope (Olympus, Tokyo, Japan), and
Optimus software (Media Cybernetics, Silver Spring, Md).
For immunoperoxidase staining, tissue sections were
rinsed in PBS, blocked with purified goat immunoglobu-
lin G (Sigma Chemical Co) for 30 minutes and then incu-
bated with the primary antibody for 1 hour (CD45 1:100,
BD Pharmingen, San Diego, Calif; ED1 1:1000, Serotec,
Oxford, United Kingdom; myeloperoxidase 1:300, Dako,
Carpenteria, Calif). Sections were incubated with a
biotinylated rabbit antimouse or mouse antirabbit sec-
ondary antibody (1:1000 Pierce, Rockford, Ill) for 1 hour
and exposed to streptavidin–horseradish peroxidase
(1:2000; Zymax, San Francisco, Calif) for 30 minutes fol-
lowed by diaminobenzidine (Innovex, Richmond, Calif)
for 3 minutes. For the contrast to be enhanced, sections
were counterstained with hematoxylin. Images were col-
lected with light microscopy.
Quantitative and morphometric analyses. Cross-
sectional intimal and medial areas within the vein grafts
were measured by use of Optimus software. Five different
regions of the graft were examined, including the distal
anastomosis, distal middle of the graft, mid-graft, proximal
middle of the graft, and the proximal anastomosis (Fig 1).
Fig 1. Diagram depicts how IJ vein grafts were processed for
morphometric and immunohistochemical analysis. DA, Distal
anastomosis; DM, distal middle; M, middle; PM, proximal mid-
dle; PA, proximal anastomosis.
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Proliferating cells within the media and intima of the
vein graft were quantified by use of Optimus software.
Images of cells expressing Ki67 were obtained, and a mask
was generated. The cell profiles were detected by use of
nuclear Hoescht staining, and an additional mask was gen-
erated. The two binary images were compared by use of
an “AND” statement, and positive profiles were extracted.
This method calculated the number of Ki67-positive cel-
lular profiles, which was then compared with the total cell
number in the field as determined by the Hoescht-stained
image. Five random fields per section were counted for
each graft region.
Statistical analysis. Results are expressed as mean ±
SEM. Differences between multiple groups were analyzed
by use of one-way analysis of variance with the Student-
Newman-Keuls post hoc test for all pairwise comparisons.
Differences between two groups were analyzed with the
Student t test (SigmaStat; SPSS, Chicago, Ill). Statistical
significance was assumed when P < .05.
RESULTS
Adenoviral gene transfer of β-galactosidase to
porcine vein grafts results in transgene expression
throughout the vessel wall. Porcine IJ vein grafts trans-
duced with AdlacZ expressed high levels (approximately
50%) of β-galactosidase in the media and to a lesser extent the
adventitia of the vessel wall 3 days after infection and implan-
tation as demonstrated by X-gal staining (Fig 2, A). By 7
days, the expression was reduced but still detectable in all
samples (Fig 2, B). Vein grafts collected 21 days after bypass
showed very little if any staining with X-gal (Fig 2, C). The
expression of β-galactosidase in the vein grafts should mirror
iNOS expression because a cytomegalovirus promoter con-
trols both cDNAs within the adenoviral constructs, and no
posttranslational regulation beyond substrate requirements
exists for either gene.
Adenoviral iNOS gene transfer to porcine vein
grafts results in significant NO synthesis. After infec-
Fig 2. Cross sections of porcine IJ veins staining for β-galactosidase activity. Vein grafts were infected with AdlacZ and collected (A) 3
(n = 4), (B) 7 (n = 4), and (C) 21 (n = 8) days after infection and bypass. (D) Vein grafts infected with AdiNOS were collected at 3
days to serve as negative control. (Original magnification ×10.)
Fig 3. Nitrite, a stable end product of NO metabolism, was
measured by Greiss reaction from the supernatant of porcine
veins infected with AdiNOS or AdlacZ. Nitrite accumulation
during the first 24 hours postinfection was measured and
expressed as nanomoles per gram of tissue. Results represent
average of all 16 pigs.
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tion of the porcine IJ veins with either AdiNOS or AdlacZ,
segments of each vein were maintained in ex vivo organ
culture. The cultured segments infected with AdiNOS pro-
duced ~5 times more NO, as measured by supernatant
nitrite, than segments infected with AdlacZ (P = .00001)
(Fig 3). These results indicate that AdiNOS infection of
vein grafts resulted in functional iNOS expression.
Infection of porcine vein grafts with either
AdlacZ or AdiNOS results in minimal inflammation
of the vessel wall. The vein grafts were examined for
neutrophil, macrophage, and lymphocyte infiltration to
determine whether the adenoviral vector or either gene
product induced inflammation. With immunoperoxidase
staining against myeloperoxidase for neutrophils (Fig 4,
A), ED1 for macrophages (Fig 4, B), and CD45 for lym-
phocytes (Fig 4, C), vessels infected with either AdlacZ
or AdiNOS demonstrated minimal inflammatory infil-
trate in the media and neointima (Fig 4). Three days
after infection, there was a slight increase in neutrophil
and macrophage infiltration of the adventitia (Fig 4, A
Fig 4. AdiNOS or AdlacZ infection of vein grafts resulted in
minimal inflammation. Staining was performed for (A) neu-
trophils, (B) macrophages, and (C) lymphocytes by use of anti-
bodies against myeloperoxidase, ED1, or CD45, respectively.
Internal positive controls consist of porcine small bowel. Negative
controls consist of sections stained with same protocol without
primary antibody. Arrows indicate positive staining cells. n = 4 for
3 and 7 day groups. n = 8 for 21 day group. (Original magnifica-
tion ×10.) L, Lumen.
A B
C
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and B) in both AdlacZ- and AdiNOS-treated grafts as
compared with grafts examined at 7 days, but the level of
inflammation was very low and insignificant for both
time points. At both 3 and 7 days, few lymphocytes were
detected (Fig 4, C). Porcine small bowel was stained for
the presence of these three markers as a positive control
(Fig 4).
iNOS gene transfer to vein grafts inhibits cellular
proliferation. Grafts were stained for Ki67 to determine
the effect of augmented NO synthesis on cellular prolifer-
ation in vein grafts. At both 3 and 7 day time points, ves-
sels infected with AdiNOS (Fig 5, B and D) qualitatively
appeared to possess fewer Ki67-positive cells as compared
with those infected with AdlacZ (Fig 5, A and C).
Quantitatively, at 3 days after bypass, iNOS gene transfer
reduced cellular proliferation by 41% versus control-
treated grafts (P = .000004, Fig 6, A). At 7 days, prolifer-
ation in AdiNOS-treated grafts was reduced 32% (P =
.0001, Fig 6, C). When different regions of the vein graft
were examined, iNOS gene transfer had the most pro-
nounced antiproliferative effect (65% reduction, P =
.0005) on the distal anastomosis at 3 days after bypass (Fig
6, B), whereas both proximal and distal sites were equally
affected at 7 days (Fig 6, D).
iNOS gene transfer to vein grafts significantly
reduced IH. Although iNOS gene transfer to vein grafts
in pigs clearly inhibited cellular proliferation throughout
the vessel wall, it was necessary to determine how this
would impact IH and medial remodeling within the
graft. At both early and late time points after gene trans-
Fig 5. Proliferative activity in vein grafts treated with AdiNOS (B, D) or AdlacZ (A, C) as determined by Ki67 staining. Vein grafts
were collected at 3 (A, B) and 7 (C, D) days after bypass and stained with antibody to Ki67. E, Sections stained without the Ki67 anti-
body served as negative controls. n = 4 for each group. (Original magnification ×10.) L, Lumen.
fer and implantation, grafts treated with AdiNOS exhib-
ited a more than 30% reduction in IH as compared with
AdlacZ-treated grafts (Fig 7, Table). At 7 days, iNOS
gene transfer reduced the intimal/medial area ratio
(I/M) by 36% versus grafts infected with AdlacZ (0.25 ±
0.03 vs 0.39 ± 0.04, respectively, P = .009) (Fig 8, A).
By 21 days after bypass, iNOS gene transfer was still asso-
ciated with a 30% reduction in neointima formation
(0.47 ± 0.03 vs 0.67 ± 0.05, respectively, P = .007) (Fig
8, C). Given that the vein graft wall was still thin at 3
days, accurate quantification of intima and media areas
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was not possible at that time point but early differences
were already visually evident (Fig 7). Measurements of
media areas at all time points did not reveal any signifi-
cant differences between AdiNOS- or AdlacZ-treated
grafts (7 days: AdiNOS 2813 ± 330 vs AdlacZ 2583 ±
219 [P = NS]; 21 days: AdiNOS 3675 ± 180 vs AdlacZ
3368 ± 160 [P = NS]).
Analysis of different regions along the vein graft
revealed regional variations in the antiproliferative effects
of NO. At 7 days, the greatest reduction in IH was mea-
sured at the distal anastomosis in AdiNOS-infected vein
Fig 6. iNOS gene transfer quantitatively decreased cellular proliferation rates at both 3- and 7-day time points as determined by Ki67
staining. Vein grafts were collected at their respective time points and stained for presence of Ki67. With a computer program, the total
number of positive staining cells was determined, and this was adjusted to the total number of nuclei present. Five random areas were
quantified for each section. A, Average proliferation rates of the entire graft for veins at 3 days. B, Proliferation rates reported by region





AdlacZ AdiNOS P value
7 d
Intimal area 1207 ± 200 714 ± 107 .03
Medial area 2583 ± 219 2813 ± 330 NS
Intimal area/medial area 0.3900 ± 0.0381 0.2484 ± 0.0342 .009
Intimal area/(intimal area + medial area) 0.2792 ± 0.0207 0.2120 ± 0.0243 .042
Lumen area/wall thickness 1.1609 ± 0.2056 1.1371 ± 0.1030 NS
21 d
Intimal area 2196 ± 121 1738 ± 88 .002
Medial area 3368 ± 160 3675 ± 180 NS
Intimal area/medial area 0.6733 ± 0.0496 0.4733 ± 0.0283 .007
Intimal area/(intimal area + medial area) 0.3932 ± 0.0168 0.3239 ± 0.0146 .0024
Lumen area/wall thickness 0.2376 ± 0.0464 0.2041 ± 0.0278 NS
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Fig 7. iNOS gene transfer reduces IH in vein grafts. Vessels infected with AdiNOS and AdlacZ were collected at 3 (n = 4), 7 (n = 4),
and 21 (n = 8) days. Images are cross sections of vein grafts. (Original magnification ×1.)
grafts as compared with AdlacZ-infected grafts (Fig 8, B).
This finding was also observed at 21 days with a statisti-
cally significant reduction in the I/M at the distal anasto-
mosis (AdiNOS 0.43 ± 0.02 vs AdlacZ 0.59 ± 0.05 [P =
.01]) (Fig 8,D).
DISCUSSION
The development of IH within vein grafts is a signifi-
cant problem that limits the clinical efficacy of bypass pro-
cedures. For this reason, we sought to evaluate the role of
iNOS gene transfer for inhibiting IH in porcine vein grafts.
In this study, adenoviral gene transfer into porcine IJ vein
grafts was associated with minimal inflammatory changes.
Expression of iNOS in these vein grafts reduced total cel-
lular proliferation by more than 30% within the vein graft,
and this translated into a similar reduction in IH up to 21
days after gene transfer and bypass. Interestingly, the
antiproliferative effect of iNOS gene transfer appeared to
be more pronounced at the distal anastomosis. Although a
significant reduction in neointima formation was observed,
medial hypertrophy and remodeling was unaffected. These
results indicate that iNOS gene transfer successfully
inhibits IH in porcine vein grafts without impairing normal
adaptive medial remodeling.
NOS gene therapy has been used to limit IH in a
number of models of vascular disease.11-15,17-21,24,25 We
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 1 Kibbe et al 163
have demonstrated effective reduction in neointima for-
mation after arterial injury from direct trauma, as well as
from immune-mediated injury seen in transplant vascu-
lopathy.14,15 The success of NOS gene transfer in inhibit-
ing vein graft IH is due to the vasoprotective properties of
NO that include inhibitory effects on platelets,3 leuko-
cytes,4 and smooth muscle cells (SMCs),5-7 and protective
effects on endothelial cells.8-10 The altered mechanical
stresses that veins used as arterial conduits are subjected to
stimulate the release of growth factors such as basic fibro-
blast growth factor, platelet-derived growth factor, and
transforming growth factor-β, that provide the mitogenic
and chemotactic drive for neointima formation.26,27
Furthermore, it has been reported that vein grafts placed
into the arterial circulation express lower functional levels
of endothelial NOS (eNOS) and NO28-30 as a result of
endothelial dysfunction or loss. Reduced NO synthesis
may underlie the propensity of vein grafts to development
of IH. Therefore the use of NOS gene transfer to restore
and augment NO production is logical.
Early studies investigating the role of NO in vein graft
IH used L-arginine supplementation in rabbit carotid
artery bypass grafts with external jugular vein.31 Davies et
al31 reported a 26.6% reduction in intimal area/intimal
area + medial area at the proximal anastomosis and 
no reduction at the distal anastomosis in animals receiving
Fig 8. iNOS gene transfer reduces I/M in vein grafts. Vein grafts were infected with either AdiNOS or AdlacZ and collected at (A, B) 7
(n = 4) and (C, D) 21 (n = 8) days after bypass for morphometric analysis. A, Mean I/M averaged over entire length of vein graft at 7 days
after bypass; B, I/M by graft region at 7 days; C, mean I/M averaged over entire length of vein graft at 21 days after bypass; D, I/M by
graft region at 21 days.
A B
C D
L-arginine. Our data demonstrated a greater reduction of
IH at the distal anastomosis with iNOS gene transfer. An
explanation for these differences may be related to the 
animal species used in these experiments. We propose that
platelet activation plays a very important role in distal
anastomotic IH. Rodents are well known to have a lesser
platelet response to vascular manipulation than human
beings and larger animals such as pigs. The difference
between the proximal and distal anastomoses may be
related to platelet activation on passage through and
aggregation at the proximal anastomosis with recruitment
and enhanced adherence of platelets at the distal anasto-
mosis with increased local release of mitogens and chemo-
tactic factors.32 The ability of NO to inhibit platelet
adherence and activation3 may explain the greater thera-
peutic effectiveness of iNOS gene transfer at that site 
in pigs undergoing carotid artery bypass. Another possible
explanation for our data may be related to the bioreactiv-
ity of NO. NO has a short half-life in the circulation, but
a higher local concentration of NO may be present at 
the distal portion of the graft because NO released from
the proximal graft could bind circulating proteins to 
form nitrosothiols.33,34 These nitrosothiols may then
release NO downstream, generating a local environment
with a higher NO concentration at the distal region of 
the graft.
More recently, Matsumoto et al18 delivered eNOS to
canine femoral vein grafts under conditions of poor runoff
and showed that intimal thickness was reduced in eNOS
treated grafts as compared with buffer-treated control
grafts. Our results indicate that iNOS delivered by an ade-
noviral vector effectively reduces vein graft IH. The iNOS
has the theoretical advantage of providing sustained, high
level NO production that is not achievable with eNOS or
the neuronal NOS isoform, which may allow therapeutic
efficacy with much lower levels of gene transfer efficiency.
Resolution of this debate will necessitate a study directly
comparing these isoforms.
Another important physiologic change that vein grafts
undergo is arterialization, characterized by medial hyper-
trophy.35 The media of a vein is thin compared with that
of an artery. Impairment of the normal arterialization
process that occurs when a vein is exposed to pulsatile,
high-pressure flow in the arterial circulation may render a
vein graft more susceptible to aneurysm formation and
graft rupture. Genetic engineering of vein grafts to resist
IH should not interfere with this remodeling process. In
porcine vein grafts treated with AdiNOS, medial hyper-
trophy still occurred and did not significantly differ from
control-treated grafts. Although iNOS gene transfer
reduced proliferative activity throughout all layers of the
vein graft wall, there appeared to be a preferential effect
on neointimal growth. The mechanism of this selective
action of NO is not clear. Although X-gal staining of
AdlacZ-treated veins revealed transgene expression in all
layers of the vessel wall, a greater distribution of trans-
duced cells was found toward the vessel lumen. NO can
also inhibit SMC migration, which is necessary for IH and
may contribute to the preferential effect on neointima for-
mation that we detected.
IH in vein grafts is an ongoing process that continues
for years. Our studies only follow the process up to 21
days. Longer-duration studies clearly need to be per-
formed, but we are encouraged by our results that the
protective effect of adenoviral-mediated iNOS gene trans-
fer may be durable in spite of limited transgene expression.
Early endothelial dysfunction and platelet activation are
the dominant stimuli for SMC migration and proliferation
in vein grafts. Because peak SMC proliferative activity
occurs in the first week after bypass,36 blocking this
process early may be sufficient to inhibit intimal growth
long-term. We and others have shown that NO is pro-pro-
liferative for endothelial cells and inhibits platelet activa-
tion.37 By protecting the endothelium and blocking
platelet activity, iNOS gene transfer may prevent the
whole mitogenic cascade that results in vein graft IH from
occurring.
A criticism of adenovirus-based gene therapies has
been the potential for a significant inflammatory response.
Studies in rabbits revealed heavy leukocyte infiltration of
arteries treated with empty adenoviral vectors, as well as
vectors carrying a marker gene.38 This inflammatory
response was associated with a dramatic increase in IH. In
our studies, minimal inflammation was detected with
either AdiNOS or AdlacZ. An explanation for this differ-
ence lies with the titer of adenoviral vector that we used.
The inflammatory changes in the above-mentioned study
were associated with use of adenoviral vectors at concen-
trations of 2 × 1010 pfu. Our experiments were performed
with viral concentrations 20-fold lower than that inflam-
matory threshold. The ability to reduce IH with such low
titers of AdiNOS is an attractive feature of iNOS that
stems from its high enzymatic-specific activity and the dif-
fusible quality of NO.
The future of iNOS gene transfer is promising. We
have now shown that adenoviral-mediated iNOS gene
transfer is beneficial in three different forms of vascular
disease: arterial injury, transplant vasculopathy, and now
vein graft IH. Although a number of gene therapy
approaches with other genes are currently being studied,
iNOS-based therapy may be one of the most attractive.
We thank Sean Albers and Romesh Draviam for their
technical assistance.
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